Arcapta

Active Ingredient(s): Indacaterol Maleate
FDA Approved: * July 1, 2011
Pharm Company: * NOVARTIS PHARMS
Category: Lungs (Pulmonary)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Arcapta Overview

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It needs to be taken only once a day,[2] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler. Medical uses A Cochrane review found benefit in lung functi...

Read more Arcapta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Indacaterol

Recent Arcapta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Indacaterol Maleate
  • Powder: 75mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Indacaterol Maleate or a similar ingredient: (1 result)

Related Arcapta Topics:

Arcapta drug interactions
Since I take arcapta neohaler for my emphysema I need to know if there is any drug intreraction with other drugs I am ta... 1 reply




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA